Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative

被引：0
|
作者：
Liu, Y. [1 ]
Cao, L. [1 ]
Che, X. [1 ]
Qiu, X. [2 ]
Li, Z. [1 ]
Yang, B. [1 ]
Wang, S. [1 ]
Qu, X. [1 ]
机构：
[1] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Liaoning, Peoples R China
[2] China Med Univ, Dept Pathol, Coll Basic Med Sci, Shenyang, Liaoning, Peoples R China
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2019年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P1920
引用
收藏
页码：531 / 532
页数：2
相关论文
共 50 条
  • [1] Macrophages are important source of PD-L1 and PD-L1 expressing on central M2 macrophages leads to the poor prognosis of NSCLC patients: Via macrophage landscape analysis for NSCLC patients with tumor PD-L1 negative
    Cao, Lili
    Che, Xiaofang
    Qu, Xiujuan
    Qiu, Xueshan
    Li, Zhi
    Yang, Bowen
    Wang, Shuo
    Liu, Yunpeng
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [2] A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative
    Ratcliffe, Marianne J.
    Sharpe, Alan
    Midha, Anita
    Barker, Craig
    Scorer, Paul
    Walker, Jill
    [J]. CANCER RESEARCH, 2016, 76
  • [3] Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
    Gumuzio, Juan
    Calleja, Veronique
    Miles, James
    Sancehz-Magraner, Lissete
    Aguirre, Fernando
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [4] Relevance of host and tumor PD-L1 in PD-L1 pathway blockade
    Kryczek, Ilona
    Lin, Heng
    Wei, Shuang
    Green, Michael
    Zou, Weiping
    [J]. JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [5] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    [J]. JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [6] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [7] PD-L1 in NSCLC cytology
    Kovacevic, M.
    Kern, I.
    Gabric, S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [8] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
    Janning, Melanie
    Kobus, Franca
    Babayan, Anna
    Wikman, Harriet
    Velthaus, Janna-Lisa
    Bergmann, Sonja
    Schatz, Stefanie
    Falk, Markus
    Berger, Lars-Arne
    Boettcher, Lisa-Marie
    Paesler, Sarina
    Gorges, Tobias M.
    O'Flaherty, Linda
    Hille, Claudia
    Joosse, Simon A.
    Simon, Ronald
    Tiemann, Markus
    Bokemeyer, Carsten
    Reck, Martin
    Riethdorf, Sabine
    Pantel, Klaus
    Loges, Sonja
    [J]. CANCERS, 2019, 11 (06):
  • [9] The efficacy of PD-L1 blockade on PD-L1 negative medulloblastoma is dependent on timing and the tumor microenvironment
    Allen, Frederick
    Dorand, Rodney Dixon
    Rauhe, Peter
    Petrosiute, Agne
    Huang, Alex Y.
    [J]. JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [10] PD-L1
    Kythreotou, Anthousa
    Siddique, Abdul
    Mauri, Francesco A.
    Bower, Mark
    Pinato, David J.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2018, 71 (03) : 189 - 194
12345